UDP-glucuronosyltransferase 1A4 (UGT1A4) polymorphisms in a Jordanian population

被引:14
作者
Hakooz, Nancy [1 ,2 ]
Alzubiedi, Sameh [2 ]
Yousef, Al-Motassem [2 ]
Arafat, Tawfiq [3 ]
Dajani, Rana [4 ]
Ababneh, Nidaa [5 ]
Ismail, Said [5 ]
机构
[1] Zarqa Univ, Fac Pharm, Zarqa 13132, Jordan
[2] Univ Jordan, Fac Pharm, Amman 11942, Jordan
[3] Jordan Ctr Pharmaceut Res, Amman 11195, Jordan
[4] Hashemite Univ, Dept Biol, Zarqa 13115, Jordan
[5] Univ Jordan, Fac Med, Amman 11942, Jordan
关键词
Drug metabolism; UGT1A4; Jordanian population; Polymorphism; CYP1A2 GENETIC POLYMORPHISMS; HUMAN LIVER-MICROSOMES; JAPANESE POPULATION; LEBANESE POPULATION; GLUCURONIDATION; PHARMACOGENETICS; TAMOXIFEN; PREVALENCE; TACROLIMUS; HAPLOTYPES;
D O I
10.1007/s11033-012-1615-y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glucuronidation is one of the most important phase II metabolic pathways. It is catalyzed by a family of UDP-glucuronosyltransferase enzymes (UGTs). One of the subfamilies is UGT1A. Allele frequencies in UGT1A4 differ among ethnic groups. The aim of this study was to determine the allelic frequency of two most common defective alleles: UGT1A4*2 and UGT1A4*3 in a Jordanian population. A total of 216 healthy Jordanian Volunteers (165 males and 51 females) were included in this study. Genotyping for UGT1A4*1, UGT1A4*2 and UGT1A4*3 was done using a well established polymerase chain reaction-restriction fragment length polymorphism test. Among 216 random individuals studied for UGT1A4*2 mutation there were 26 individuals who were heterozygous, giving a prevalence of 12% and an allele frequency of 6.5%. Only one individual was homozygous for UGT1A4*2. The UGT1A4*3 mutation was detected as heterozygous in 9 of 216 individuals indicating a prevalence of 4.2% and allele frequency of 3.5%. Three individuals were homozygous for the UGT1A4*3 indicating a prevalence of 1.4%. The prevalence of UGT1A4*2 is similar to the Caucasians but different from other populations whilst the UGT1A4*3 prevalence in the Jordanian population is distinct from other populations. Our results provide useful information for the Jordanian population and for future genotyping of Arab populations in general.
引用
收藏
页码:7763 / 7768
页数:6
相关论文
共 32 条
[1]   Study the polymorphism of CYP3A5 and CYP3A4 loci in Iranian population with laryngeal squamous cell carcinoma [J].
Azarpira, Negar ;
Ashraf, Mohamad Javad ;
Khademi, Bigan ;
Darai, Masumeh ;
Hakimzadeh, Afsoon ;
Abedi, Elham .
MOLECULAR BIOLOGY REPORTS, 2011, 38 (08) :5443-5448
[2]   CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population [J].
B'chir, Fatma ;
Pavanello, Sofia ;
Knani, Jalel ;
Boughattas, Sami ;
Arnaud, Maurice J. ;
Saguem, Saad .
LIFE SCIENCES, 2009, 84 (21-22) :779-784
[3]   Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects [J].
Bae, Jung-Woo ;
Choi, Chang-Ik ;
Lee, Jin-Hee ;
Jang, Choon-Gon ;
Chung, Myeon-Woo ;
Lee, Seok-Yong .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (01) :39-45
[4]   A GENETIC-STUDY OF THE JORDANIANS [J].
BANERJEE, B ;
SAHA, N ;
DAOUD, ZF ;
KHALAF, FH ;
QUDAH, H .
HUMAN HEREDITY, 1981, 31 (02) :65-69
[5]   A pharmacogenetics study of the human glucuronosyltransferase UGT1A4 [J].
Benoit-Biancamano, Marie-Odile ;
Adam, Jean-Philippe ;
Bernard, Olivier ;
Court, Michael H. ;
Leblanc, Marie-Helene ;
Caron, Patrick ;
Guillemette, Chantal .
PHARMACOGENETICS AND GENOMICS, 2009, 19 (12) :945-954
[6]  
Brooker R.J., 2005, GENETICS ANAL PRINCI
[7]   Pharmacogenetics of Coumarin Dosing: Prevalence of CYP2C9 and VKORC1 Polymorphisms in the Lebanese Population [J].
Djaffar-Jureidini, Isabelle ;
Chamseddine, Nabil ;
Keleshian, Sose ;
Naoufal, Rania ;
Zahed, Laila ;
Hakime, Noha .
GENETIC TESTING AND MOLECULAR BIOMARKERS, 2011, 15 (11) :827-830
[8]   Variation of hepatic glucuronidation:: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4 [J].
Ehmer, U ;
Vogel, A ;
Schütte, JK ;
Krone, B ;
Manns, MP ;
Strassburg, CP .
HEPATOLOGY, 2004, 39 (04) :970-977
[9]   Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population [J].
Gaikovitch, EA ;
Cascorbi, I ;
Mrozikiewicz, PM ;
Brockmöller, J ;
Frötschl, R ;
Köpke, K ;
Gerloff, T ;
Chernov, JN ;
Roots, I .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (04) :303-312
[10]   Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans [J].
Ghotbi, Roza ;
Christensen, Magnus ;
Roh, Hyung-Keun ;
Ingelman-Sundberg, Magnus ;
Aklillu, Eleni ;
Bertilsson, Leif .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (06) :537-546